33.55
-0.02(-0.06%)
Currency In USD
| Previous Close | 33.57 |
| Open | 33.06 |
| Day High | 33.97 |
| Day Low | 33.06 |
| 52-Week High | 34.64 |
| 52-Week Low | 14.59 |
| Volume | 673,098 |
| Average Volume | 440,868 |
| Market Cap | 979.28M |
| PE | -76.25 |
| EPS | -0.44 |
| Moving Average 50 Days | 23.64 |
| Moving Average 200 Days | 21.14 |
| Change | -0.02 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $1,567.76 as of November 07, 2025 at a share price of $33.55. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $702.18 as of November 07, 2025 at a share price of $33.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapiesFRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosc
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
GlobeNewswire Inc.
Oct 26, 2025 7:05 PM GMT
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high quality, novel or uniqueFRIENDSWOOD, Texas, Oct.
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
GlobeNewswire Inc.
Oct 24, 2025 8:05 AM GMT
This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NE